Clinical Data

Chanhassen – October 28, 2026 -- Every patient with investigator-assessed clinical deterioration in an exploratory 15-patient glioblastoma analysis showed sustained increases in lactate dehydrogenase (LDH) during treatment, Alpheus Medical, Inc. reported at the ESMO Congress 2026 in Madrid.

Poster 4289P tracks LDH trajectories in 15 recurrent glioblastoma patients

The clinical-stage oncology company presented the data from its first-in-human study of Porphyrin Metabolite Activation (PoMA). The cohort comprised 15 patients with MGMT-unmethylated recurrent glioblastoma. Instead of relying on a single LDH value, the analysis examined how LDH changed over time and how those trajectories related to clinical and radiographic disease status.

Cambridge, Mass. – October 28, 2026 -- CREATE Medicines will present preclinical data showing complete B cell depletion in lymph nodes, spleen and bone marrow after low doses of its in vivo CAR-T therapy at the APLAR 2026 Congress in Seoul, running October 28 to November 1 at the COEX Convention & Exhibition Center.

Adam Raff presents mouse and primate data on October 31

Adam Raff, MD, PhD, SVP of Autoimmune Clinical Development, will deliver the oral abstract "In Vivo Generation of CAR-T Cells for the Treatment of B-cell Mediated Autoimmune Disease" in Abstract Session 2. The data come from mice and non-human primates. They show that low doses cleared B cells from the deep tissues where autoimmune disease takes hold.

Athens – October 27, 2026 -- Month 6 interim data comparing single-dose Cecolin 9 with Gardasil 9 were presented at the 38th Annual Conference of the International Papillomavirus Society (IPVS 2026), while final results from the Phase III SHINE I study are not expected until 2028.

Navrongo researcher presents Month 6 analysis of PATH's SHINE I study

Dr. Nana A. Ansah of Ghana's Navrongo Health Research Centre presented the interim analysis of PATH's Single-dose HPV Immunobridging Study with New Vaccines (SHINE I; CVIA 104). The Phase III, double-blind, randomized, multinational study runs in Ghana and the Philippines. It compares the immunogenicity and safety of single-dose Cecolin 9, developed by Xiamen Innovax Biotech Co., Ltd. (IX), with Gardasil 9.

Participants include girls aged 9–14 and young women aged 15–20.

Bad Homburg, Germany – October 19, 2026 -- Fresenius Medical Care reports that 74% of more than 10,000 high-volume hemodiafiltration (HvHDF) treatments delivered on its 5008X CAREsystem in the United States reached the target convective dose of 23 liters or greater. The company will present the data at the American Society of Nephrology's Kidney Week 2026, held October 21-25 in Denver, Colorado.

U.S. real-world data shows HvHDF delivery matches European targets

The company says the findings show HvHDF can be delivered in routine U.S. clinical practice with treatment targets comparable to those reported in Europe. Fresenius researchers are studying U.S. implementation as adoption expands. The work feeds the company's BEACON-US research initiative, which examines online HDF therapy and patient outcomes in the U.S.

San Diego – October 19, 2026 -- Capricor Therapeutics (NASDAQ: CAPR) will present 24-month skeletal muscle and cardiac data from its Phase 3 HOPE-3 trial of Deramiocel in Duchenne muscular dystrophy (DMD) at the World Muscle Society Congress, weeks ahead of an FDA PDUFA target action date of November 22, 2026.

The 31st Annual Congress (WMS 2026) runs September 29 to October 3, 2026, in Hiroshima, Japan. Capricor will deliver one late-breaking poster and one oral presentation on Deramiocel, plus two preclinical posters from its StealthX exosome platform.

HOPE-3 24-month cohort reaches 82 of 106 randomized patients

Of the 106 patients randomized in HOPE-3, 82 reached the 24-month time point: 40 originally assigned to Deramiocel and 42 to placebo. The data build on the 12-month results reported previously.

Stockholm – October 19, 2026 -- Sobi will present seven accepted abstracts on Aspaveli/Empaveli (pegcetacoplan) at the American Society of Nephrology (ASN) Kidney Week 2026, running 21–25 October in Denver, Colorado, including two oral and five poster presentations.

Oral sessions report 76-week outcomes in two rare kidney diseases

The two oral presentations cover 76-week outcomes with Aspaveli/Empaveli in C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN). According to Sobi, the data show maintained proteinuria reduction and stabilised eGFR. The package includes a paediatric subgroup analysis from the VALIANT study and its VALE extension.

Indianapolis – October 19, 2026 -- Eli Lilly and Company (NYSE: LLY) will present first Phase 1 data for its investigational FRα-targeting antibody-drug conjugate sofetabart mipitecan (Sofe-M) in platinum-sensitive ovarian cancer (PSOC) at the European Society for Medical Oncology (ESMO) Congress, October 23–27 in Madrid, alongside updated data across lung, thyroid and breast cancer programs.

Sofe-M plus bevacizumab data in PSOC backs ongoing Phase 3 trial

Lilly will give a rapid oral presentation on the first Phase 1 results for Sofe-M combined with bevacizumab in PSOC. The company says the data support the ongoing Phase 3 clinical trial of Sofe-M in PSOC.

North Chicago – October 19, 2026 -- AbbVie will present new and updated data on seven solid tumor assets at the 2026 European Society for Medical Oncology (ESMO) Congress, October 23-27 in Madrid, the company's most expansive ESMO program to date. The data span lung, colorectal, ovarian, prostate and gastric cancers, across antibody-drug conjugates (ADCs), bispecific antibodies and combination regimens.

Temab-A posts 30% response rate in colorectal cancer combination

In a Phase 1 study of previously treated advanced colorectal cancer, Temab-A (telisotuzumab adizutecan) at 2.4 mg/kg plus bevacizumab delivered a 30% overall response rate after a median follow-up of 18.2 months. Median overall survival reached 14.7 months with the combination (n=30), against 10.2 months for standard of care (n=20), regardless of c-Met expression. No new safety signals were observed. The combination is now in the global Phase 3 AndroMETa-CRC-560 study.

North Chicago – October 17, 2026 -- AbbVie (NYSE: ABBV) is presenting 20 new scientific abstracts from its inflammatory bowel disease (IBD) portfolio at the 2026 United European Gastroenterology (UEG) Week, held October 17-20 in Barcelona, Spain. The data cover long-term and real-world outcomes for Skyrizi (risankizumab) and Rinvoq (upadacitinib) in Crohn's disease (CD) and ulcerative colitis (UC).

Risankizumab maintains remission in UC through week 96

In the COMMAND study, patients on risankizumab 180 mg reached as-observed clinical remission rates of 54.0%-73.1% at week 96. Endoscopic remission rates were 38.8%-53.5%. The ranges span advanced therapy-naïve and advanced therapy-experienced patients, and the study reports up to three years of maintenance treatment.

TORONTO – October 14, 2026 -- Patients treated with whole-gland TULSA were more than twice as likely to preserve both erectile function and pad-free continence at six months as those who had robotic radical prostatectomy (risk ratio 2.1; p=0.004), according to CAPTAIN trial data. Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) presented the results among five abstracts at the 15th Interventional MRI Symposium in Boston.

CAPTAIN trial shows whole-gland TULSA cut complication hospitalizations to 0.7% versus 6.3% for robotic surgery

CAPTAIN is the first fully enrolled, multicenter randomized controlled trial to compare the TULSA Procedure directly with robotic radical prostatectomy in localized intermediate-risk prostate cancer. Whole-gland TULSA also showed statistically superior preservation of flaccid penile length at one month.